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EXPLORING THE ROLE OF GLYCOPROTEIN 130 IN HOMING 
SHAIDA OMID 
ABSTRACT 
Coordinated lymphocyte adhesion and migration is a hallmark of the adaptive 
immune response in both physiological and pathological conditions. Therefore, 
understanding the mechanisms underlying lymphocyte trafficking at the molecular level 
may provide novel targets for the treatment of immune-mediated diseases. The controlled 
migratory pattern of lymphocytes, commonly referred to as homing, is critically 
dependent on specialized microvasculature and is facilitated by the expression of 
adhesion molecules and signaling chemokines. During steady state conditions, homing of 
immune cells occurs continuously in the lymph nodes due to the constitutive expression 
of homing molecules, whereas during an inflammatory condition, a reactive up regulation 
of these adhesion molecules is necessary for immune cell trafficking to take place. 
The dynamics of immune cell recruitment, demonstrated by intravital microscopy, 
showed that lymphocyte adhesion in the target tissue’s microvascular bed is mostly 
restricted to the post-capillary and collecting venules, whereas arterioles and capillaries 
can not support this interaction. High shear stress exerted by fluid dynamics in the lumen 
of venules requires intravascular lymphocytes to anchor using receptor molecules that 
form mechanically stable bonds with counter receptors in the vascular wall (von Andrian 
& Mackay, 2000). These molecules play a key role in lymphocyte binding and facilitate 
the directed migration of lymphocytes by functioning as a tissue specific recognition 
molecule differentially expressed on the surface of lymph node ECs (von Andrian & 
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Mackay, 2000). Specialized venular ECs found in lymph nodes and Peyer’s Patches (PPs) 
called high endothelial venules (HEVs) constitutively express on their surface a 
specialized type of this homing molecule called addressins, allowing for the continuous 
recruitment of lymphocytes during steady state conditions. Elsewhere in the body, ECs 
must be activated by exposure to inflammatory mediators in order to allow 
transendothelial migration to the inflamed tissue.  
There is strong evidence to show the homing signature of a lymphocyte is 
dependent on the expression of adhesion molecules and chemokine receptors on the cell 
surface as well as their ligands expressed by the venular endothelium. Here, we 
hypothesize that the cytokine signaling receptor subunit glycoprotein 130 (gp130) is a 
functional requirement for eliciting an effective recruitment of lymphocytes to secondary 
lymphoid organs during steady states. Glycoprotein 130 is a signaling subunit involved 
with the interleukin-6 (IL-6) family of cytokines. Previous studies done in the lab have 
shown that this glycoprotein is over expressed in the venular versus non-venular 
endothelial cells, indicating a potential role of gp130 in lymphocyte homing during 
steady state conditions.  
This hypothesis was tested by analyzing short term homing assays using donor β-
actin-GFP splenocytes, with recipient litter-mate controls and recipient conditional or 
inducible conditional knockout mouse models that lack gp130 expression on ECs. By 
comparing the homing abilities of GFP+ splenocytes to various secondary lymphoid 
organs in wild type versus knockout mouse models, we were able to determine that 
gp130 expression on the endothelial cell compartment does have a role in lymphocyte 
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homing, demonstrated by impaired homing capabilities evident in only the knockout 
mice. 
Identifying the function of gp130 expressed by venular ECs and its role in 
lymphocyte recruitment during steady state conditions may lead to a better understanding 
of the immune system and it’s complexity during the dynamic maintenance of 
homeostatic health.   
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INTRODUCTION 
Overview of the Immune System 
Lymphocytes are a well-characterized type of white blood cells that play a key 
role in maintaining the health and homeostasis of our bodies. As an important cellular 
component of the adaptive immune system, these cells have the unique capacity to mount 
an antigen specific response. 
Lymphocytes are generated in the primary lymphoid organs, arising from 
hematopoietic stem cells in the bone marrow. Before entering circulation, pre-mature 
lymphocytes are subjected to a selection process and tested for auto reactivity. Once in 
the periphery, these naïve T cells and B cells navigate through the body in search of their 
cognate antigen. Following identification of cognate antigen, lymphocytes are activated 
to undergo a dynamic maturation and differentiation process to enhance their ability to 
detect those antigens, and in doing so B and T lymphocytes increase their ability to defeat 
and eliminate pathogens that are the source of the targeted antigens.  
Given the vastness of the human body, the challenge then comes with how it is 
these lymphocytes encounter their cognate antigen. To address this, the immune system 
has evolved secondary lymphoid organs (SLO) to orchestrate the detection of antigen by 
lymphocytes and consequently trigger an immune response. SLOs include peripheral 
lymph nodes (PLNs), mesenteric lymph nodes (MLNs), spleen, Peyer’s Patches, 
appendix and tonsils (Girard & Springer, 1995). SLOs are connected to the parenchyma 
by the lymphatic system consisting of blind-ending vessels lined by lymphatic 
endothelial cells (LECs). Afferent lymphatics are found only in lymph nodes and 
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function to bring in the interstitial fluid from the parenchyma to the draining lymph 
nodes. Efferent lymphatics exist in all SLOs including the spleen and Peyer’s patches and 
drain the collected fluid out of SLOs. Collectively, this network of lymphatic vessels is 
responsible for draining interstitial fluids of different tissues through the various SLOs, 
ultimately ending in the thoracic duct for re-entry into the blood circulation. This fluid 
called lymph can contain any debris, particulate material, soluble particles including 
microbes, and antigen presenting cells (APCs). 
Not only can free antigen enter SLOs via lymphatic vessels, but specialized 
antigen presenting cells (APCs) called dendritic cells (DCs), have the capacity to enter 
lymph nodes via the afferent lymphatics as well (Figure 1). DCs are abundantly present 
in the SLOs themselves, and are common to areas in direct contact with the outside 
environment, such as the mucosa, skin, and intestine. Once these peripheral DCs acquire 
antigen and enter the lymphatics, they drain to proximal lymph nodes where they present 
antigen on their cell surface for recognition by lymphocytes a process known as antigen 
presentation. By such interactions with T lymphocytes, these antigen presenting DCs 
have the critical role of orchestrating the adaptive immune response.  
This process of antigen delivery from the periphery increases the efficiency of 
lymphocytes encountering antigen, ultimately allowing for a more immediate and robust 
immune response. Unlike DCs, lymphocytes that have not yet recognized their cognate 
antigen, also known as naïve, do not enter SLOs via afferent lymphatics. Instead, they 
penetrate specialized postcapillary venular endothelial cells called high endothelial 
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venules (HEVs) located in the cortex of all lymphoid organs except for the spleen 
(Girard, Moussion, & Förster, 2012a; von Andrian & Mempel, 2003). 
In addition to DCs capturing antigen and draining to SLOs, the immune system 
has developed another mechanism aiming to efficiently detect antigen by lymphocytes. 
This design promotes circulating lymphocytes to travel to the SLOs in a non-random 
fashion and importantly, to remain there when cognate antigen has been detected. The 
process of directed lymphocyte migration to SLOs at steady state is referred to as 
homing. It is important to recognize that homing to SLOs serves the purpose of 
enhancing the availability of cognate antigen for lymphocyte detection. This action is 
attributable to the sustained chemoattractant gradient produced in the cortex of lymphoid 
organs by the stromal architecture comprised of fibroblastic reticular cells (FRCs) and 
follicular dendritic cells (FDCs) that provide the lymph node with distinct chemokines 
that recruit lymphocytes. In addition, HEVs have been well characterized to 
constitutively synthesize and present chemokines and surface adhesion proteins involved 
in recruiting lymphocytes in a process known as the multistep adhesion cascade. 
In the case of an immune response, lymphocytes will also be recruited to sites of 
inflammation following the similar multistep principles, although, this recruitment 
process is distinguishable in that non-lymphoid organs require the presence of 
inflammatory signals to mediate venular endothelium lymphocyte trafficking (Girard & 
Springer, 1995). 
Lymphocytes necessitate a dynamic interaction with ECs in order to adhere to the 
vessel wall and subsequently migrate through the endothelial barrier to enter into the 
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tissue, a process known as diapedesis. Prior to this transmigration, the lymphocyte must 
first overcome the high shear stress exerted by the luminal fluid. This process has been 
well studied and characterized by a series of steps that make up the multistep adhesion 
cascade.  
 
 
 
 
 
Figure 1. Schematic of lymph node structure. Diagramed is a lymph node depicting 
the B cell zones (B), T-cell zones, high endothelial venules (HEVs), fibroblastic reticular 
cell (FRC) conduits and other constituents involved in the immune response. Image from 
Miyasaka & Tanaka, (2004).  
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Multistep Adhesion Cascade 
During steady-state, naïve T cells display cell surface receptor that allow for their 
homing to lymph nodes. Once immune cells identify antigen and are activated, changes 
take place in the cell surface expression of certain receptors and molecules involved in 
the homing process (Hart et al., 2010).  
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Figure 2. Schematic of the multistep adhesion cascade. Adhesion molecules and 
receptors involved in lymphocyte homing. (a) Homing in lymph nodes. (b) Homing in 
Peyer’s Patch. Image from von Andrian & Mackay, (2000). 
 
 
The first step of the multistep adhesion cascade encompasses receptors located on 
the surface of lymphocytes and on ECs called selectins that bind to interact with counter 
receptors on the cellular partner. Selectin molecules engage in low affinity interactions 
with HEV glycoproteins called addressins, ultimately allowing the lymphocyte to roll 
along the endothelium (Figure 2) (von Andrian & Mackay, 2000). Lymphocyte subsets 
have the capacity to distinguish between HEVs in peripheral versus mucosal lymph nodes 
based, in part, on the expression of specific homing receptors. In addition, HEV tissue-
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specific expression of vascular addressins also contributes to the capacity of lymphocytes 
to distinguish different lymphoid organs (Berg, Robinson, Warnock, & Butcher, 1991). 
HEVs in the peripheral lymph node express the peripheral lymph node addressin (PNAd), 
and lack mucosal addressin cell adhesion molecule 1 (MAdCAM-1) that is expressed on 
HEVs in mesenteric lymph nodes and Peyer’s Patches (von Andrian & M'Rini, 1998). 
These differences in addressin molecules create a recognizable distinction between the 
peripheral lymph nodes, mesenteric lymph nodes, and Peyer’s Patches. Thus, this divided 
expression of specific addressin molecules on HEVs is partially responsible for 
promoting the directed migration of lymphocytes to distinct lymph nodes (Butcher, 
Williams, Youngman, Rott, & Briskin, 1999). 
Lymphocyte rolling along the endothelium is initiated and mediated by selectin 
binding with carbohydrate-based ligands (Figure 2). This interaction allows the 
lymphocyte to be in closer proximity to activating chemokines found on the surface of 
HEVs (von Andrian & Mackay, 2000). Subsequent cell signaling induces the activation 
of a conformational change in integrin proteins into their active state. Integrins 
specifically function to support firm adhesion of the lymphocyte to the endothelial wall. 
In addition, the selective expression of integrin molecules on the surface of lymphocytes 
can play a role in regulating lymphocyte trafficking.  
Stronger adhesive interactions between the HEV and the patrolling immune cell 
provided by integrin activation allow the cell to go from rolling along the endothelium to 
ultimately sticking. Similar cascades are seen when immune cells are homing to non-
lymphoid organs. In such cases the venular endothelium is responsible for engaging in 
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immune cell trafficking by upregulating the appropriate adhesion molecules necessary for 
the multistep adhesion cascade (Hart et al., 2010).  
 
General Review of Glycoprotein 130 
For years the cytokine receptor signaling subunit gp130 has been a target of 
scientific study due to it’s association with many different pathologies, such as its 
expression in tumor cell environments (Xu & Neamati, 2013). Functional analysis of 
gp130 reveals that it is a signaling subunit on the receptors for the IL-6 family of 
cytokines (Kishimoto, Akira, Narazaki, & Taga, 1995a; Taga, 1996), (Figure 3). The IL-6 
family of cytokines includes IL-6, IL-11, IL-27, oncostatin M (OSM), leukemia 
inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), 
cardiotrophin-like cytokine (CLC), and recently introduced, neuropoietin (NPN) (Figure 
3) (Taga & Kishimoto, 1997), (Vlotides, Zitzmann, Stalla, & Auernhammer, 2004), 
(Derouet et al., 2004). Since these signaling proteins all share the common signal 
transducer it is not surprising that they have potential overlaps in function (Fasnacht & 
Müller, 2008). Partial heterogeneity in the signaling can be seen by the different protein 
cytokines based on some requiring gp130 subunits to be heterodimers or homodimers for 
proper signal transduction (Fasnacht & Müller, 2008; Kishimoto, Tanaka, Yoshida, 
Akira, & Taga, 1995b).    
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Figure 3. Schematic of the cytokine receptor subunit glycoprotein 130 signaling. 
Display of the different ligands known to interact with the signaling subunit gp130 in a 
homodimer or heterodimer conformation with other various receptor subunits. The 
interleukin-6 (IL-6) ligands associate with gp130 homodimers. The gp130 heterodimer 
associated receptor signaling includes the ligands leukemia inhibitory factor (LIF), ciliary 
neurotrophic factor (CNTF), cardiotrophonin 1 (CT-1) and oncostatin M (OSM). These 
cytokines reocognized by different combinations of the various receptor subunits (IL-6R, 
LIFR, CNTFR, OSMR) form complexes with the gp130 subunit and mediate signaling 
pathways that are involved with intercellular activation of the Janus-activated kinase-
signal transducer and activator of transcription (JAK-STAT) and the mitogen-activated 
protein kinase (MAPK) pathways. Image is from (Bauer, Kerr, & Patterson, 2007). 
 
 
Straight knockout mice that lack the gp130 gene in all cells show early lethality at 
birth or shortly after, about 12.5 days depending on the background of mice (Yoshida et 
al., 1996). This highlights gp130’s salient role in development. Experiments have also 
been performed that have postnatally induced deletion or inactivation of the gp130 gene 
in different mouse models. Such postnatal deletion results in many defects including 
neurological, cardiac, hematopoietic, immunological, hepatic and pulmonary (Betz et al., 
1998). 
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Conditional KO mouse models 
In the mouse models we use, a gene targeted for deletion is floxed when it is 
flanked by two loxP sequences (St-Onge, Furth, & Gruss, 1996). This targets the gene to 
be consequently excised by the Cre-recombinase enzyme, creating the conditional 
knockout mouse (Figure 4). In order to have an organ-specific or cell-specific deletion, 
the Cre-recombinase enzyme is under the control of a cell specific promoter of choice 
(Kohan, 2008).  
The McEver lab used such a conditional mouse model to study the role of gp130 
in bone marrow. They produced a conditional knockout strain that lacked gp130 
selectivly on hematopoietic and endothelial cells (Yao et. al., 2005). This was 
accomplished through the use of the Tie2 promoter/enhancer to drive Cre expression, 
knowing that Tie2 is an endothelial cell marker and transiently expressed in 
hematopoietic stem cells (Yao, Yokota, Xia, Kincade, & McEver, 2005). 
Tie2Cre+/gp130fl/fl mice specifically lack gp130 on the endothelial and hematopoietic 
compartments and thus are a suitable model to study the role of gp130 in homing. 
VE-Cadherin (VE-Cad) is an intercellular junction protein only expressed on 
endothelial cells. Thus the VE-Cad promoter can be used to induce expression of 
tetracycline Transactivator protein (tTA) selectively in endothelium (St-Onge et al., 
1996). tTA, under control of the VE-Cad promoter in the inducible conditional knockout 
mouse model will activate the tet-operator (tet-O). In turn, the element tet-O promoter 
drives expression of the Cre-recombinase gene resulting in endothelium specific deletion 
of floxed genes (St-Onge et al., 1996).  
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 There are two known inducible conditional knock out systems, the ‘tet-off’ and 
‘tet-on’ system, both regulated by an exogenous ‘trigger’ molecule, doxycycline (DOX) 
(Figure 4) (Baron & Bujard, 2000). For our purposes, when gene deletion is to occur, 
administration of DOX is stopped, allowing for the tTA to bind the VE-Cad- tet-O 
promoter to drive endothelial Cre expression resulting in deletion of the floxed gp130 
gene (Figure 4). It is important to note that the establishment of the VE-Cad-gp130 KO 
mouse model provides control on the timing of gene deletion and allows for endothelial-
specific deletion to occur in contrast to the Tie2Cre-gp130 KO that exhibits loss of gp130 
on the endothelial and hematopoietic compartment starting in the prenatal phase.  
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Figure 4. Schematic representation of conditional knockout mouse models. (a) The 
conditional knockout model with the target gene (black rectangle) flanked by two loxP 
sequences. Floxed genes are subsequently excised by the Cre-recombinase, resulting in 
gene deletion as depicted. (b) The inducible conditional knockout model with and 
without doxycycline (DOX) systems. Image depicts tet-off system that showing that upon 
DOX removal Cre-recombinase is expressed and results in gene deletion, specifically in 
the endothelial cells. Image courtesy of Blanche Gauthier.  
 
 
Figure 4 : Genes and mechanisms involved in the obtaining of knockout mice (personnal creation) 
  
 
Figure 4 : Genes and mechanisms involved in the obtaining of knockout mice (personnal creation) 
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The Present Study 
Ensuing prior transcriptome analysis of venular endothelial, non-venular 
endothelial and lymphatic endothelial cell subsets done by Dr. A. Thiriot in the von 
Andrian lab, it was discovered that gp130 is overexpressed on venules relative to non-
venules in all tissues studied including lymph node (LN), skin, adipose tissue and colon. 
As venular endothelial cells are known for engaging in lymphocyte trafficking via the 
multistep adhesion cascade, collection of this data evoked the question of gp130’s role in 
homing. 
Although many transgenic knockout models studying the effects of gp130 
expression have shown the importance of the signaling subunit in many different tissue 
and cell types, the role of gp130 in lymphocyte homing, at steady state or under 
inflammatory conditions in adult tissue, remains to be identified.  
In order to efficiently study the role of gp130 in lymphocyte homing, selective 
deletion of gp130 needs to occur in cell types associated with lymphocyte trafficking. 
Thus, we used a conditional knockout (Tie2Cre-gp130 KO) and an inducible conditional 
knock (VE-Cad-gp130 KO) out system to provide us with mouse models that have cell-
specific deletions of gp130.  
        We explored the role of gp130 in the homing of immune cells using both mouse 
models. To address this, the described mouse models with modified expression of gp130 
were utilized and subsequent homing assays were performed. These data provide 
evidence that gp130-dependent signaling in endothelial and hematopoietic cells 
contributes significantly to lymphocyte homing. 
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Our first goal was to identify any role that gp130 expression may have in 
lymphocyte trafficking. Next, given confirmation of the necessity of gp130 expression 
for functional lymphocyte recruitment to some SLOs, we wanted to understand the 
effects of gp130 expression on lymphocyte trafficking. Specifically, we aimed to identify 
the cell types responsible for engaging with the signaling subunit and to recognize those 
cell types required to express the signaling subunit during lymphocyte homing. Taken 
together, in this project we investigated the potential role of gp130 in lymphocyte homing 
in order to better understand lymphocyte recruitment dynamics at steady state or during 
inflammatory settings.  
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Specific Aims 
Taking advantage of these the conditional knockout and inducible conditional knockout 
mouse models, we have presumed the following project aims: 
 
1) In order to investigate the role of glycoprotein 130 in lymphocyte homing we have:  
a. Evaluated novel phenotypes of mice deficient in gp130 on endothelial and 
hematopoietic cells using a conditional knockout mouse model (Tie2Cre-gp130 
KO) and characterize the composition of the lymphoid organs. 
b. Evaluated any defects in homing of donor β-actin-GFP splenocytes in Tie2Cre-
gp130 KO, Tie2Cre-gp130 Het and Tie2Cre-gp130 WT recipients by performing 
a short-term homing assay. 
 
2) To determine the molecular mechanism behind endothelial gp130’s involvement in 
lymphocyte homing to secondary lymphoid organs we have: 
a. Established and characterize an inducible conditional knockout mouse model 
(VE-Cad-gp130 KO). 
b. Examine the cellularity and composition of different organs to detect any 
modifications. 
c. Evaluated lymphocyte homing capabilities in these mice by performing a short-
term homing experiment. 
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METHODS 
Animal Model 
All experiments were performed in accordance with the National Institute of 
Health guidelines and all mouse protocols were approved by the Institutional Animal 
Care and Use Committee of Harvard Medical School. The C57BL/6 mice used in this 
paper came from JAX Labs and the Charles River Laboratory. Experimental knockout 
strains were either made or maintained as breeders by careful breeding strategies and 
specific crossings of different strains of mice, all with a C57BL/6 background.  
Conditional gp130 knockout mice that are lacking gp130 in the endothelial cell 
and hematopoietic compartment were Tie2Cre+/gp130fl/fl and gp130fl/fl mice were 
provided by Dr. Roger P. McEver (Oklahoma Medical Research Foundation). Genotypes 
of mice were assessed via polymerase chain reaction (PCR) on genomic DNA. 
Conditional knockouts are distinguished by their Tie2Cre+/gp130fl/fl genotype. Control 
mice for our experiments were littermates of the knockouts and recognized by genotype 
analysis as being Tie2Cre-/gp130fl/fl or Tie2Cre+/gp130+/+ since they shared the same 
phenotype of wild type mice by expressing gp130 without any modifications.  
The inducible conditional knockout mouse model under control of the VE-Cad 
promoter was created in our laboratory’s animal facility. VE-Cad+/tTA+ and tet-OCre+ 
mice were provided by Dr. Laura Benjamin and Tanya Mayadas. VE-Cad+/tTA+/tet-
OCre+ mice were bred with gp130fl/fl to create the inducible conditional knockout. 
Doxycycline (Bio-serv) (DOX) was administered via diet at the dose concentration of 
200mg/kg. DOX was removed and replaced with a normal non-fat p53 diet from the 
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inducible conditional knockout animals at the time of birth. The wild-type, heterozygous 
floxed, and homozygous floxed gp130 alleles were detected by genotyping on genomic 
DNA. Primers for the genes are listed. 
Gp130 gene: gp130 A: 5’ ACG TCA CAG AGC TGA GTG ATG CAC-3’ , gp130 B: 5’ 
GGC TTT TCC TCT GGT TCT TG-3’ , gp130 floxed allele =550bp, WT allele = 400bp. 
Cre gene : Cre A: 5’ AGG TGT AGA GAA GGC ACT TAG C-3’, Cre B: 5’ CTA ATC 
GCC ATC TTC CAG CAG G-3’, Cre allele =400bp, WT allele = not detected. 
tTA gene: tTA Fwd 5’- GAC GCC TTA GCC ATT GAG AT -3’ , tTA Rvs 5’- CAG 
TAG TAG GTG TTT CCC TTT CTT -3’ , tTA allele = 350 bp, WT allele = not detected 
 In these knockout systems, heterozygous expression of the Cre-recombinase 
enzyme is sufficient for excision of a floxed gene, therefore homozygous or heterozygous 
expression of the Cre-recombinase gene is not distinguished in this paper.  
 
Antibodies 
For immunohistology and flow cytometry analysis, the following antibodies were 
used: anti-glycoprotein 130/gp130/CD130 (eBioscience, clone K6P130), anti-CD31 
(clone 390), anti-CD45.1 (clone A20), anti-CD45.2 (clone 104), anti-TCRβ (H57-597), 
anti-CD19 (clone 6D5), anti-NKp46/CD335 (clone 29A1.4), anti-CD3 (clone 17A2), 
anti-gp38/podoplanin (clone 8.1.1), 7-AAD cell viability dye from Biolegend.  
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Short-term Homing Assay 
Cell suspension of β-actin-GFP cells was prepared by harvesting the spleen of a 
β-actin-GFP reporter mouse and subsequently isolating splenocytes. Spleen was 
homogenized and treated with red blood cell lysis buffer for one minute. The reaction 
was then quenched with five milliliters of HBSS media with 2% fetal bovine serum 
(FBS). Tyrpan blue-negative live cells were counted using a hemocytometer. Cell 
suspension of 10x106 cells/200ul was prepared and injected intravenously by tail vein per 
mouse. This cell suspension input was then counted using the Acurri (BD) and analyzed 
with Flow cytometry (FACS Canto (BD)) for GFP+ expression. Mice were sequentially 
sacrificed 1.5 hours after injection. Mouse pool of peripheral lymph nodes (inguinal, 
axillary and brachial), spleen, mesenteric lymph nodes, and Peyer’s patch organs were 
harvested, homogenized, prepared via filtering, stained and analyzed by FACS for the 
presence of GFP+ cells.  
Half the peripheral lymph nodes were subjected to an endothelial cell isolation 
harvest, and stained and analyzed via FACS for expression of gp130 for the VE-Cad-
gp130 strain.  
 
Statistical analysis: 
All data are presented as mean ± SEM unless noted otherwise. Statistical analysis 
used Student t-Test and one-way ANOVA accordingly.  
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RESULTS 
To determine the role of glycoprotein 130 (gp130) in lymphocyte homing, we 
used a mouse model that has specific deletion of gp130 in endothelial cells (ECs). Here 
the conditional knockout mouse Tie2Cre-gp130 was evaluated for novel phenotypes and 
lymphocyte homing deficiencies.  
Total number of hematopoietic (CD45+) cells, were counted in the lymphoid 
organs of Tie2Cre-gp130 WT, Tie2Cre-gp130 Het, and Tie2Cre-gp130 KO mice. In the 
blood, cellularity was increased significantly in Tie2Cre-gp130 KO mice compared to 
Tie2Cre-gp130 WT or Tie2Cre-gp130 Het, with no differences distinguished when 
comparing the Tie2Cre-gp130 WT with Tie2Cre-gp130 Het blood CD45+ cell counts 
(Figure 5). This trend is amplified in the spleen, where total hematopoietic cell numbers 
in Tie2Cre-gp130 KO mice is significantly higher compared to Tie2Cre-gp130 WT or 
Tie2Cre-gp130 Het mice (Figure 5). This enhanced cellularity demonstrates noticeable 
splenomegaly, an observation in accordance with published data by (Yao, Yokota, Xia, 
Kincade, & McEver, 2005), characterizing the phenotypes of these mice. 
The total number of CD45+ cells in peripheral lymph nodes (PLNs) are 
significantly reduced but not abolished in Tie2Cre-gp130 KO mice compared to Tie2Cre-
gp130 WT (Figure 5), and there were no significant differences between the WT and 
Tie2Cre-gp130 Het mice (Figure 5). Hematopoietic cell counts in cervical lymph nodes 
(cLN) and auricular lymph nodes (aurLN) also demonstrated significant decreased 
numbers of hematopoietic cells in the Tie2Cre-gp130 KO compared to Tie2Cre-gp130 
Het used as control (Figure 5). 
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Figure 5. Abolished cellularity in Tie2Cre-gp130 KO blood and secondary lymphoid 
organs. Total number of hematopoietic cells (CD45+) from various secondary lymphoid 
organs in Tie2Cre-gp130 WT (white), Tie2Cre-gp130 Het (grey) and Tie2Cre-gp130 KO 
(black) mice. Total CD45+ cell counts were taken from the blood and the following 
secondary lymphoid organs: spleen, peripheral lymph nodes (PLNs, pool of inguinal 
lymph nodes, brachial lymph nodes, and axillary lymph nodes), cervical lymph nodes 
(cLN), auricular lymph nodes (aurLN), in Tie2Cre-gp130 WT, Tie2Cre-gp130 Het, and 
Tie2Cre-gp130 KO mice. Blood is expressed as number of CD45+cells/ml of blood. In 
blood, spleen and PLNs, n=8 mice in Tie2Cre-gp130 WT genotype, n=6 mice in the 
Tie2Cre-gp130 het genotype, n=10 mice in the Tie2Cre-gp130 KO genotype. One-way 
ANOVA, n.s., not significant. *, P<0.05,**, P<0.01,***, P<0.0001. In cLN and aurLN 
n=3 mice in the Tie2Cre-gp130 Het genotype, n=3 mice in the Tie2Cre-gp130 KO 
genotype. Student t-Test, n.s., not significant. *, P<0.05,**, P<0.01. Data are shown as 
mean ± SEM. 
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Knowing that gp130 is expressed on endothelial and hematopoietic cells of wild-
type but not the conditional knockout strains based on experimental data from (Yao et al., 
2005), we anticipated that the deficiency of gp130 would affect lymphocyte migration 
into lymphoid organs. To address this, a short-term homing assay was performed. For this 
purpose, splenocytes from a transgenic β-actin-GFP reporter mouse were isolated and 
injected intravenously into recipient Tie2Cre-gp130 WT, Tie2Cre-gp130 Het, and 
Tie2Cre-gp130 KO mice. 1.5 hours after injection, we quantified the number of GFP+ 
cells in secondary lymphoid organs such as spleen, PLNs, and MLNs, counted by FACS. 
Donor GFP+ cells that had accumulated in recipient lymphoid organs were counted using 
flow cytometry (Uchimura et al., 2005). We used the spleens as organ controls given that 
lymphocyte recruitment to the spleen does not follow the multistep adhesion cascade 
mechanism.  
Blood samples and homing of donor cells to recipient spleens were comparable in 
all three strains, as expected (Figure 6). In the Tie2Cre-gp130 KO mice, we detected a 
significant reduction of GFP+ homed cells in both PLNs and MLNs as compared to both 
Tie2Cre-gp130 WT and Tie2Cre-gp130 Het mice (Figure 6). Such effects of diminished 
homing were not seen when comparing the Tie2Cre-gp130 Het to Tie2Cre-gp130 WT 
mice (Figure 6). 
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Figure 6. Reduced homing capabilities of β-actin-GFP splenocytes in Tie2Cre-gp130 
KO mice. Splenocytes from β-actin-GFP mice were injected intravenously into age 
matched Tie2Cre-gp130 WT (white), Tie2Cre-gp130 Het (grey) and Tie2Cre-gp130 KO 
(black) mice. Splenocytes derived from β-actin-GFP transgenic mice were detected in (a) 
blood, (b) spleen and (c) peripheral lymph nodes (PLNs, pool of inguinal lymph nodes, 
brachial lymph nodes, and axillary lymph nodes), and mesenteric lymph nodes (MLNs) 
of each mouse as analyzed by flow cytometry. The distribution of GFP+ cells was 
analyzed 1.5 hours after tail vein injection and is expressed as number of GFP+ cells/106 
cells injected, gated among lymphocytes in each organ. Blood is expressed as the number 
of GFP+ cells/106 cells injected/ml of blood. n=8 mice in the Tie2Cre-gp130 WT 
genotype, n=6 mice in the Tie2Cre-gp130 Het genotype, n=10 mice in the Tie2Cre-
gp130 KO genotype. One-way ANOVA n.s., not significant, **, P<0.01. ***, P<0.0001. 
Data are shown as mean ± SEM. 
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Figure 7. Tie2Cre-gp130 KO mice exhibit a reduced number of Peyer’s Patches 
regardless of sex. Number of Peyer’s Patches found in (a) male and (b) female mice 
from Tie2Cre-gp130 WT (white), Tie2Cre-gp130 Het (grey) and Tie2Cre-gp130 KO 
(black) strains. n=6 to 7 mice of each genotype. One-Way ANOVA n.s., no significance, 
***, P<0.0001. Data are shown as mean ± SEM. Image courtesy of Dr. Yasuhiro 
Nemoto. 
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Lymphocyte recruitment to Peyer’s Patches could not be assessed because of the 
unexpected dramatic decrease in PPs number in Tie2Cre-gp130 KO mice (Figure 7). 
Tie2Cre-gp130 WT and Tie2Cre-gp130 Het mice displayed no differences in the number 
of Peyer’s Patches harvested (Figure 7). Males and females in each group were compared 
to determine if sex had a role in the exhibited loss of PPs found in the Tie2Cre-gp130 
KO, but the results demonstrate that sex of the mouse is not a significant factor in this 
morphological defect (Figure 7). 
To investigate this conspicuous phenotype further and to rule out that the defect in 
Peyer’s Patches could have been an effect resulted from a smaller morphology of the 
small intestine (SI), measurements of the lengths and weights of the harvested small 
intestine were recorded (Figure 8A, 8C, 8E). The lengths and weight of the colon were 
measured for control (Figure 8B, 8D, 8E). No significant differences were seen in the 
morphologies as measured by the lengths and weights of harvested small intestine in the 
different mouse strains, confirming that the decrease in the number of PPs is due to 
developmental defects in this conditional knockout strain (Figure 8). 
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Figure 8.  No differences in length or weight of intestines in Tie2Cre-gp130 KO. (a) 
Length of small intestine measured in mm, (b) length of colon measured in mm, (c) 
weight of small intestine measured in mg, and (d) weight of colon measured in mg. 
Measurements were taken in Tie2Cre-gp130 WT, Tie2Cre-gp130 Het and Tie2Cre-gp130 
KO mice. n=5 to 8 mice in each genotype. One-Way ANOVA n.s., no significance. Data 
are shown as mean ± SEM. 
 
 
L
en
gt
h 
of
 sm
al
l i
nt
es
tin
e 
(m
m
)
L
en
gt
h 
of
 c
ol
on
 (m
m
)


 
 






  

 





	



  
A B 
W
ei
gh
t o
f s
m
al
l i
nt
es
tin
e 
(m
g)

W
ei
gh
t o
f c
ol
on
 (m
g)







 
 
 
  


 
 





  
C D
n.s. 
n.s. n.s. 
n.s. 
n.s. n.s. 
n.s. 
n.s. n.s. 
n.s. 
n.s. n.s. 
	  26 
Given the defect in homing capabilities and morphological defects in PPs 
development, we wanted to understand the biology behind this phenotype in the Tie2Cre-
gp130 KO model. Because in Tie2Cre-gp130 KO mice gp130 is lacking in both the 
endothelial as well as the hematopoietic compartment, we aimed to determine which cell 
type was responsible for the significant characteristics and phenotypes observed. To 
address this question, we created an inducible conditional knockout mouse that allowed 
for the deletion of the gp130 gene to be restricted to the endothelial cell compartment 
using the VE-Cadherin (VE-Cad) promoter (Figure 4, 9).  
By selectively cross breeding a VE-Cad-tTA+/tet-OCre+ mouse, with a gp130 
floxed (gp130fl/fl) mouse strain we were able to obtain an inducible conditional knockout 
(VECad-tTA+/tet-OCre+/gp130fl/fl) (Figure 4). Doxycycline (DOX) was administered via 
a food diet and was removed at birth. Subsequent experiments were performed at least 
eight weeks after DOX removal to ensure gp130 gene deletion. 
To confirm inducible gene deletion on the endothelium, flow cytometry analysis 
was performed. Blood and peripheral lymph node samples collected from the VE-Cad-
gp130 KO mice showed a lack of gp130 expression on endothelial cells (Figure 9). This 
data shows that gp130 is absent in both blood endothelial cells (BECs) and lymphatic 
endothelial cells (LECs) confirming the inducible conditional system for gp130 gene 
deletion is functional (Figure 4, 9).  
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Figure 9. VE-Cad-gp130 KO mice lack gp130 expression only on the endothelial cell 
compartment. Gating strategies of peripheral lymph node samples analyzed by flow 
cytometry for expression of gp130 on the endothelium of VE-Cad-gp130 WT (white) and 
VE-Cad-gp130 KO (black) mice. Our FACS gating strategy is the following: (a) we gate 
on large population (size) of single cells and live cells (7AAD -) cells, we exclude 
CD45+ hematopoietic cells and (b) gate on blood endothelial cells (BEC) as gp38-
CD31+ and lymphatic endothelial cells (LEC) as gp38+CD31+. BEC and LEC are 
further differentiated into gp38-CD31+gp130+ and gp38+CD31+gp130+, respectively. 
(c) Frequency of gp130+ endothelial cells among total endothelial cells quantified in 
peripheral lymph node (PLNs) from Tie2Cre-gp130 WT and Tie2Cre-gp130 KO mice. 
(d) Geometric mean fluorescent intensity (GeoMFI) expressed in blood samples analyzed 
by flow cytometry for expression of gp130 on T and B lymphocytes in VE-Cad-gp130 
WT and VE-Cad-gp130 KO mice. n=4 mice in each genotype. Student t-Test, n.s., no 
significance, *, P<0.05. Data are shown as mean ± SEM. 
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VE-Cad-gp130 KO mice did display slight splenomegaly as assessed by the 
weight of VE-Cad-gp130 KO spleens compared to wild type (Figure 10). In addition, 
surprisingly, no defect in PPs number was seen in the VE-Cad-gp130 KO mice compared 
to that of VE-Cad-gp130 WT (Figure 11).  
 
 
 
 	   
     
 
 
 
Figure 10. VE-Cad-gp130 KO displays mild splenomegaly. Graph of spleen weights 
from control VE-Cad-gp130 WT compared to VE-Cad-gp130 KO mice with doxycycline 
removed for 18-20 weeks. n=8 mice in each genotype. Student t-Test, *, P<0.05. Data are 
shown as mean ± SEM.  
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Figure 11. VE-Cad-gp130 KO mice do not lack Peyer’s patches. (A) Number of 
Peyer’s Patches (PP) from VE-Cad-gp130 KO and VE-Cad-gp130 WT mice counted. (B) 
Lengths of small intestine and (C) colon from VE-Cad-gp130 KO and VE-Cad-gp130 
WT mice were measured in mm. Student t-Test, n.s., no significance. n=4 mice of each 
genotype. Data are shown as mean ± SEM. 
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Figure 12. Cellularity in VE-Cad-gp130 KO mice. Total cell counts in various 
secondary lymphoid organs and blood in VE-Cad-gp130 WT (white) and VE-Cad-gp130 
KO (black) mice. Total cell numbers taken from (a) blood and secondary lymphoid 
organs including (b) spleen, (c) peripheral lymph nodes (PLNs, pool of inguinal lymph 
nodes, brachial lymph nodes, and axillary lymph nodes), (d) mesenteric lymph nodes 
(MLNs), and (e) Peyer’s Patches (PPs), from VE-Cad-gp130 WT and in VE-Cad-gp130 
KO mice that were removed from doxycycline for 18-20 weeks. Blood is expressed as 
number of cells/ml of blood. n=4 mice of each genotype. Student t-Test, n.s., no 
significance. Data are shown as mean ± SEM. 
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Having confirmed that gp130 is expressed in endothelium of VE-Cad-gp130 WT 
but not VE-Cad-gp130 KO mice, we next asked whether the homing defect observed in 
the conditional Tie2Cre-gp130 KO mouse persists in the inducible conditional model, 
addressing if the homing deficiency was due to the lack of gp130 on the endothelium or 
the hematopoietic compartment. To gain insight into the role of gp130 on the endothelial 
compartment in lymphocyte trafficking, a short-term homing assay was performed. 
Following the same homing protocol, splenocytes from a transgenic β-actin-GFP reporter 
mouse were isolated and injected intravenously into recipient VE-Cad-gp130 WT and 
VE-Cad-gp130 KO mice. 1.5 hours after cell injection, we quantified donor GFP+ cells 
that had accumulated in recipient lymphoid organs using flow cytometry, with blood and 
spleen samples taken as controls (Uchimura et al., 2005).  
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Figure 13. Lymphocyte recruitment is impaired in VE-Cad-gp130 KO mice. Homing 
of β-actin-GFP splenocytes in VE-Cad-gp130 WT (white) and in VE-Cad-gp130 KO 
(black) mice. Splenocytes derived from β-actin-GFP+ transgenic mice homing to 
peripheral lymph nodes (PLNs, pool of inguinal lymph nodes, brachial lymph nodes, and 
axillary lymph nodes), mesenteric lymph nodes (MLNs), Peyer’s Patches (PPs) and 
spleen in VE-Cad-gp130 WT and in VE-Cad-gp130 KO mice that were removed from 
doxycycline for 18-20 weeks. The distribution of GFP+ cells was analyzed 1.5 hours 
after tail vein injection and expressed as the number of GFP+ cells/106 cells injected, 
gated among lymphocytes in each lymphoid organ. Blood is expressed as number of 
GFP+ cells/106 cells injected /ml of blood. PPs is expressed as number of GFP+ cells/106 
cells injected / Peyer’s patch. n=4 mice in each genotype. One-way ANOVA, n.s., no 
significance. *, P<0.05, **, P<0.01. Data are shown as mean ± SEM. 
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VE-Cad-gp130 KO mice have lymphocyte homing reduced in the peripheral 
lymph nodes compared to VE-Cad-gp130 WT recipients similar to what was seen in the 
Tie2Cre-gp130 KO mice (Figure 13). Homing to mesenteric lymph nodes was also 
significantly diminished in the VE-Cad-gp130 KO mice compared to VE-Cad-gp130 WT 
recipients (Figure 13). Homing to Peyer’s Patches was severely impaired in the VE-Cad-
gp130 KO recipient mice (Figure 13). Blood samples and homing of donor splenocytes to 
recipient spleen organs were comparable in VE-Cad-gp130 KO mice to that of VE-Cad-
gp130 WT, as expected (Figure 13). These data indicate that gp130 expression does play 
a role in lymphocyte homing, on the endothelial compartment. 
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DISCUSSION 
The recruitment of lymphocytes from the blood circulation to the lymph nodes is 
essential to generating an adaptive immune response and maintaining an immune 
surveillance program during an inflammatory episode. Here we provide in vivo evidence 
for the critical role of the signaling subunit glycoprotein 130 (gp130) in the homing of 
lymphocytes under steady state conditions by analyzing conditional and inducible 
conditional knockout mouse models. We report that the absence of the cytokine receptor 
signaling subunit glycoprotein 130 on endothelial and hematopoietic cells in the 
conditional knockout (Tie2Cre-gp130 KO) and on endothelial cells only in the inducible 
conditional knockout mice (VE-Cad-gp130 KO) results in lymphocyte homing 
deficiencies. In addition to the impaired homing of lymphocytes, unexpected differences 
in secondary lymphoid organ compositions observed in the two strains lead us to propose 
that gp130-signaling plays at least two distinct roles in cellular recruitment dynamics; one 
to be on the level of the endothelium for lymphocyte homing and the other, we 
hypothesize, on the level of hematopoietic cells for stem cell precursor recruitment. 
First, Tie2Cre-gp130 KO and VE-Cad-gp130 KO mice have significant 
lymphocyte homing deficiencies across all lymph nodes tested, such as peripheral lymph 
nodes and mesenteric lymph nodes, suggesting that the loss of gp130 on endothelial cells 
impairs recruitment of lymphocytes to lymph nodes. 
Second, Tie2Cre-gp130 KO mice display reduced numbers of Peyer’s Patches 
without any reduction or absence in other secondary lymphoid organs, suggesting that 
gp130-mediated signaling, on the endothelial and/or hematopoietic compartment, is 
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critical for the development of Peyer’s Patches. In contrast, VE-Cad-gp130 KO mice 
display no impairment in Peyer’s patch development, despite the lack of gp130 on the 
endothelium. This suggests that the absence of Peyer’s Patches in Tie2Cre-gp130 KO 
mice is a phenotype related to gp130-signaling at the level of the hematopoietic 
compartment. 
In addition, Tie2Cre-gp130 KO mice display a significant reduction in total 
hematopoietic cell number within the various lymph nodes tested, while lymphocyte 
numbers in blood and spleen where enhanced, a phenotype not shared by the VE-Cad-
gp130 KO strain. It is unlikely that the reduced hematopoietic cell number observed in 
Tie2Cre-gp130 KO mice causes the reduction in lymphocyte homing capabilities. This 
interpretation is also supported by the VE-Cad-gp130 KO mice that did not have 
significant decreases in their hematopoietic cell numbers yet displayed similar 
impairments in lymphocyte homing. Thus, we favor the notion that the impaired 
lymphocyte homing capabilities in Tie2Cre-gp130 KO lymph nodes does not cause the 
reduced number of hematopoietic cells found in these organs. Furthermore, VE-Cad-
gp130 KO mice did not share a decreased cellularity in lymph nodes, as seen in Tie2Cre-
gp130 KO mice, suggesting that the reduced total hematopoietic cell number is 
attributable to gp130 deletion on the hematopoietic compartment and not the 
endothelium. 
Interestingly, despite the uncommon patterns in Peyer’s Patch development 
between the Tie2Cre-gp130 KO and the VE-Cad-gp130 KO strains, there was a shared 
characteristic of splenomegaly, albeit milder, in the VE-Cad-gp130 KO mice. This 
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suggests a dual role for gp130 expression, such that gp130 plays a role in maintaining 
sufficient lymphocyte trafficking on the level of the endothelium, as well as the 
hematopoietic compartment, with dual ablation of the signaling subunit creating the 
severe splenic compensatory response demonstrated by the Tie2Cre-gp130 KO mouse 
splenomegaly. 
Although the mechanism by which the deletion of gp130 mediated signaling 
decreases lymphocyte homing capabilities is currently unknown, we hypothesize that 
signaling pathways activated by gp130 may serve to balance the net expression of 
adhesion molecules and/or chemokines involved in the multistep adhesion cascade. In 
order to address this, future experiments will identify the role of gp130 at the level of the 
multistep adhesion cascade. To investigate the adhesion molecules involved in 
lymphocyte homing present in VE-Cad-gp130 KO and Tie2Cre-gp130 KO mice, we will 
focus on the systematic analysis of the components of each of the three steps of the 
multistep adhesion cascade. 
To determine the molecular mechanism behind endothelial cell expression of 
gp130 and its involvement in lymphocyte recruitment we will first investigate the level of 
expression of the addressin molecules PNAd and MAdCAM-1 specific to HEVs in PLNs 
and PPs, respectively, as well as other specific adhesion molecules including VCAM-1, 
ICAM-1, and ICAM-2 (Girard et al., 2012). This will be done in the conditional knockout 
Tie2Cre-gp130 mice and the inducible conditional knockout VE-Cad-gp130 mice. We 
will also examine the structure of the lymph nodes by staining for B cell zones and T cell 
zones. Research by Yao et. al., (2013), studying neutrophil recruitment in Tie2Cre-gp130 
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KO mice shows that gp130 deficient mice express normal levels of ICAM-1 on the 
surface of endothelial cells, thus we do not predict any difference in the VE-Cad-gp130 
KO strain (Yao et al., 2013). 
Next, to directly observe the effect of endothelial cell gp130 deletion in VE-Cad-
gp130 KO mice on the rolling of lymphocytes in lymph node HEV, we will employ the 
use of intravital microscopy (IVM). To investigate rolling deficiencies, we will focus on 
L-selectin expression on the lymphocyte, and HEV sialomucins (N-glycans, 6-sulpho 
sialyl Lewis X) that induce rolling (Girard et al., 2012). Following this interaction is cell 
sticking that is triggered by lymphocyte CCR7 binding to HEV expressed of CCL21. 
This causes cell-signaling activation of (lymphocyte associated antigen 1) LFA-1 integrin 
into its active conformation (Warnock, Askari, Butcher, & Andrian, 1998). LFA-1 
activated integrin interacts with ICAM-1and ICAM-2, on the surface of HEVs and the 
adherent cells crawl fro a short distance within the HEV lumen until final transmigration 
(Girard et al., 2012). We can investigate all of these phases by examining the expression 
patterns of proteins involved with each step using IVM and confocal imaging analysis 
(Halin, Mora, Sumen, & Andrian, 2005). 
To rule out the probable effects of diminished lymphocyte homing in theVE-Cad-
gp130 KO mice due to the lack of blood perfusion in the organ, and therefore attributing 
the role of gp130 on the multistep adhesion cascade, we will analyze intraluminal shear 
forces by intravital microscopy. Specifically, analysis of VE-Cad-gp130 KO Peyer’s 
Patch organs will identify if lymphocyte homing deficiency is a result of a default in the 
multistep adhesion cascade or rather associated with the lack of blood perfusion as a 
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results of a PPs organ defect. To highlight gp130 involvement with the multistep 
adhesion cascade, we will start by analyzing the rolling and sticking fractions of the 
lymphocytes along the high endothelial venules of PPs. 
Studies have shown that the alteration of one of the fundamental adhesion 
molecules or chemokines, on the level of the lymphocyte or venular endothelium, will 
results in drastic modifications in trafficking capabilities, indicating the fundamental role 
that such molecules posses. Research by Chen et al., (2004), demonstrates that 
lymphocyte adhesion activation of L-selectin by fever-range thermal stress depends on 
IL-6 signaling, in particular the expression of gp130 receptor subunit (Chen et al., 2004). 
This study also determined that the thermal response involved the specific IL-6 family of 
cytokines IL-11, LIF and OSM (Chen et al., 2004). In accordance with this observation, 
we speculate a strong candidate for the gp130-signaling events required for proper 
lymphocyte homing to be OSM, also known to be involved in angiogenesis and 
development (Yao, Pan, Setiadi, Patel, & McEver, 1996). In addition, studies by Wojta at 
el., (2012), on the cytokine signaling receptor explain that OSM induced pluripotent 
effects on human endothelial cells, with its proliferative signals limited to the 
microvascular cells, and not recognized as responsive on macrovascular human umbilical 
venular endothelial cells (HUVEC) as seen by the lack of proliferation following OSM 
stimulation (Demyanets, Huber, & Wojta, 2012).  
The association of gp130 with OSM may link the lymphocyte homing system to 
organogenesis. As described previously, the loss of gp130 has a significant impact on a 
variety of biological events. To identify a role of gp130 in the expression of adhesion 
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molecules, in particular L-selectin and OSM gp130 signaling, further analysis on the 
expression levels of these molecules involved, as well as functionality assessments must 
be made.  
 Furthermore, we will assess the role of steady state gp130 expression on Peyer’s 
Patch organ development on the level of the lymphoid tissue inducer cells (LTi), a cell 
type responsible for the organogenesis of Peyer’s Patches (Cherrier & Eberl, 2012; 
Strober, 2010). LTi is positive for the hematopoietic marker CD45 and thus targeted by 
the conditional knockout system, which supports the hypothesis that LTi stem progenitor 
cells are involved in our gp130 deleted mouse models (Mebius et al., 2001). If in fact 
gp130 is expressed on these cells, as will be determined with future experiments, this will 
support the conclusion that gp130 expression on the hematopoietic compartment, not the 
endothelial cell is responsible for causing the phenotype of defected PPs in the Tie2Cre-
gp130 model, and not in the VE-Cad-gp130. Further supporting the hypothesis that this 
progenitor cell is the cause for the secondary lymphoid organ defects observed is that LTi 
cells are only known for being involved with the Peyer’s patch organogenesis, and not 
other secondary lymphoid organ development, consistent with our phenotype of only 
diminished PPs in the conditional knockout (Honda et al., 2001).  
The defect in Peyer’s Patch number is a novel characteristic of these mice that has 
not been previously published, although, other transgenic mouse models have been 
shown to have similar defects in PPs development, such as the CXCL13 deficient mice 
(Honda et. al., 2001). CXCL13 is a cytokine produced by stromal fibroblastic reticular 
cells and follicular dendritic cells found in the lymph node cortex. It is involved with the 
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intra-nodal migration of B lymphocytes, directing the cells via a chemoattractant 
chemical gradient to the B cell follicles located along the periphery near the sub-capsular 
sinus (Figure 1). B cells express the CXCR5 receptor for CXCL13, and without this 
ligand binding interaction B cell follicles will not form thus effecting PPs development. 
To address this, we will assess the number of B cells as well as the level of expression of 
associated chemokines such as, CXCL13, in the PPs of the Tie2Cre-gp130 KO mice.  
Another transgenic mouse strain lacking PPs is the Wiskott-Aldrich syndrome 
protein (WASP)- deficient strain (Snapper et al., 2005). WASP has been described to 
play a role in cellular locomotion through regulating surface receptor signaling to the 
actin cytoskeleton (Snapper et al., 2005). It has also been shown that lymphocytes have a 
reduced tethering and migration when WASP-deficient (Snapper et. al., 2005). Also, 
similar to the VE-Cad-gp130 KO homing characteristics, mice with WASP-deficient 
lymphocytes are demonstrated to show significantly more impairment in lymphocyte 
homing to PPs than to other secondary lymphoid organs (Snapper et. al., 2005). To 
address the probable role of gp130 signaling and its effects on lymphocyte trafficking by 
way of WASP interaction, we will also analyze the expression patterns of WASP protein 
in various secondary lymphoid organs. 
Finally, to further our understanding of the role of gp130 in the spleen we will 
identify any defects in structure by performing immunohistochemical analysis for B cell 
and T cell zones. Imaging will be done with confocal microscopy and staining for splenic 
lymphoid nodules, periarteriolar lymphoid sheaths and red pulp. 
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Taken together, we can conclude that the lack of gp130 expression on the 
endothelium is responsible for the lymphocyte homing deficiencies in both knockout 
mouse models, while the lack of gp130 on the hematopoietic compartment is responsible 
for driving physiological abnormalities observed, including decreased cellularity in 
lymphoid organs, increased cellularity in systemic blood and spleen, as well as a 
profound defect in PP formation. Further analysis of this potentially dichotomous role of 
gp130 expression on endothelial cells and hematopoietic cells is necessary, and important 
to determining the underlying mechanisms by which gp130 plays a role in lymphocyte 
homing and homeostasis. Gaining a mechanistic understanding of the role that gp130 
expression plays on the endothelium and specifically it’s interactions with lymphocyte 
homing will bring us one step closer to better understanding the vast number of 
pathologies associated with this signaling subunit, and ultimately better the scientific 
understanding of lymphocyte homing dynamics in inflammatory processes (Silver & 
Hunter, 2010).  
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